Autoimmune markers in slow type 1 diabetes: Confrontation to type 1 diabetes

Diabetes and Metabolism

Volumn 26, Issue 5, 2000, Pages 353-360

  Desailloud, R ^a   Fajardy, I ^a   Vambergue, A ^a   Prevost, G ^a   Pigny, P ^a   Fontaine, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

GAD antibodies; IA 2 antibodies; ICA; LADA; Slow type 1 diabetes

Indexed keywords

ADULT; AGED; ARTICLE; DIAGNOSTIC VALUE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULINEMIA; MAJOR CLINICAL STUDY; PATHOPHYSIOLOGY;

ADULT; AGE OF ONSET; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; WEIGHT LOSS;

EID: 0033670846     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Report of the expert committee on the diagnosis and classification of diabetes mellitus
2. A comparison of childhood and adult type I diabetes mellitus
3. The pathogenesis and prevention of diabetes in adults
4. Type I diabetes masquerading as type II diabetes
5. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
6. Prevalence of insulin deficiency among initially non-insulin dependent middle-aged diabetic individuals
7. GAD antibodies in NIDDM: Ten year follow-up from the diagnosis
8. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin dependent onset of disease
9. β-cell function in relation to islet cell antibodies during the first 3 year after clinical diagnosis of diabetes in type II diabetic patients
10. Small doses of subcutaneous insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM
11. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
12. Insulin dependent diabetes mellitus (IDDM): 12th international histocompatibility workshop stud
13. Crucial points at diagnosis: Type 2 diabetes or slow type 1 diabetes
14. Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes. The 2-year analysis of the german BABYDIAB study
15. Prospective analysis of islet cell antibodies in children with type 1 (insulin-dependent) diabetes
16. Five-year follow-up of islet cell antibodies in type 2 (non-insulin-dependent) diabetes mellitus
17. Immunogenetic and clinical characterisation of slowly progressive IDDM
18. Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: Slowly progressive IDDM - The clinical characteristics and pathogenesis of the syndrome
19. Serial changes in the prevalence of islet cell antibodies and islet cell antibody titer in children with IDDM of abrupt or slow onset
20. The role of late-onset autoimmune diabetes in white familial NIDDM pedigrees
21. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus
22. Antibodies to glutamate decarboxylase (GAD) remain highly prevalent in adult-onset autoimmune diabetes: A comparison of population based studies in 15-34 and 0-15 year old swedish diabetic patients
23. GAD antibodies seldom disappear in slowly progressive IDDM
24. Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with polyendocrine disease
25. Distinct genetic and immunological features in patients with onset of IDDM before and after age 40
26. Prevalence of diabetes-specific autoantibodies in patients at risk for adult onset diabetes mellitus
27. Differential expression of glutamic acid decarboxylase in rat and human islets
28. Gamma-aminobutyric acid outside the mammalian brain
29. Heterogeneity in the occurence of a subset of autoantibodies to glutamic acid decarboxylase in autoimmune polyendocrine patients with islet cell antibodies
30. Inverse relation between humoral and cellular immunity to glutamic acid decarboxylase in subjects at risk of insulin-dependent diabetes
31. Relationship between GAD antidody and residual beta-cell function in children after overt onset of IDDM
32. Autoantibodies in IDDM primarily recognize the 65000-Mr rather than the 67000-Mr isoform of glutamic acid decarboxylase
33. High diagnostic sensitivity of glutamate decarboxylase autoantibodies in insulin-dependent diabetes mellitus with clinical onset between age 20 and 40 years
34. Prediction of IDDM in the general population. Strategies based on combinations of autoantibody markers
35. Dual-parameter model for prediction of type I diabetes mellitus
36. Glutamate decarboxylase antibody levels predict rate of β-cell decline in adult-onset diabetes
37. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA)
38. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies
39. Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes
40. IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus
41. Immunological heterogeneity in type 1 diabetes: Presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease
42. Immunology in diabetes: An update
43. Antibodies to islet 37k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity
44. Combined analysis of long-term anti-beta cell humoral reactivity in type l diabetes with and without thyroid disease